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ABSTRACT
Objectives: Chronic obstructive pulmonary disease
(COPD) is a major cause of morbidity and mortality.
Iron deficiency, with or without anaemia, is associated
with other chronic conditions, such as congestive heart
failure, where it predicts a worse outcome. However,
the prevalence of iron deficiency in COPD is unknown.
This observational study aimed to determine the
prevalence of iron deficiency in COPD and associations
with differences in clinical phenotype.
Setting: University hospital outpatient clinic.
Participants: 113 adult patients (65% male) with
COPD diagnosed according to GOLD criteria (forced
expiratory volume in 1 s (FEV1): forced vital capacity
(FVC) ratio <0·70 and FEV1 <80% predicted); with age-
matched and sex-matched control group consisting of
57 healthy individuals.
Main outcome measures: Prevalence of iron
deficiency, defined as: any one or more of (1) soluble
transferrin receptor >28.1 nmol/L; (2) transferrin
saturation <16% and (3) ferritin <12 µg/L. Severity of
hypoxaemia, including resting peripheral arterial
oxygen saturation (SpO2) and nocturnal oximetry;
C reactive protein (CRP); FEV1; self-reported
exacerbation rate and Shuttle Walk Test performance.
Results: Iron deficiency was more common in
patients with COPD (18%) compared with controls
(5%). In the COPD cohort, CRP was higher in patients
with iron deficiency (median 10.5 vs 4.0 mg/L,
p<0.001), who were also more hypoxaemic than their
iron-replete counterparts (median resting SpO2 92% vs
95%, p<0.001), but haemoglobin concentration did not
differ. Patients with iron deficiency had more self-
reported exacerbations and a trend towards worse
exercise tolerance.
Conclusions: Non-anaemic iron deficiency is
common in COPD and appears to be driven by
inflammation. Iron deficiency associates with
hypoxaemia, an excess of exacerbations and, possibly,
worse exercise tolerance, all markers of poor
prognosis. Given that it has been shown to be
beneficial in other chronic diseases, intravenous iron
therapy should be explored as a novel therapeutic
option in COPD.
INTRODUCTION
The effects of iron deﬁciency on haemoglo-
bin concentration are well known, but less
well recognised are the earlier consequences
prior to the development of anaemia. In
otherwise healthy individuals, these include
reduced aerobic exercise capacity, higher
levels of fatigue and impaired cognition.1 2
Iron deﬁciency is common in patients with
congestive heart failure, where it has been
identiﬁed as an independent predictor of
mortality.3 In this setting, it has been shown
that treatment with intravenous iron improves
functional outcomes regardless of the pres-
ence or absence of anaemia, and regardless
of whether or not haemoglobin concentra-
tions change following iron therapy.4 5
Strengths and limitations of this study
▪ The patients who took part in the study were
comprehensively evaluated and had disease
severity assessed according to a variety of well-
validated measures, many known to predict
outcome in chronic obstructive pulmonary
disease (COPD).
▪ The definition of iron deficiency was conservative
and based on several different validated indices.
▪ The study cohort was of limited size compared
to other COPD cohorts.
▪ The patient cohort was almost exclusively
Caucasian with moderately severe COPD; the
findings may not apply to other ethnic groups or
those with different disease severity.
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Iron has a pivotal role in the pathways that cells use to
sense and respond to hypoxia,6 with iron deﬁciency to
an extent mimicking hypoxia. This may underlie some
of the symptomatology associated with iron deﬁciency.7
A fall in alveolar oxygen tension causes hypoxic pulmon-
ary vasoconstriction (HPV), and chronic hypoxia can
lead to irreversible remodelling of the pulmonary vascu-
lature and pulmonary hypertension. The inﬂuence of
iron on HPV is demonstrated by the striking effects of
experimental manipulation of iron levels in healthy
humans. Iron depletion augments the pulmonary hyper-
tensive response to hypoxia, while iron loading greatly
attenuates the phenomenon.8 9
In chronic obstructive pulmonary disease (COPD),
iron deﬁciency could be particularly deleterious since
hypoxaemia is common, is a marker of disease severity,
and is important in the pathophysiology and extrapul-
monary manifestations of the condition.10 Pulmonary
hypertension is one of the strongest predictors of
decreased survival in COPD and is signiﬁcantly driven
by hypoxia;11 it may also be augmented by iron deﬁ-
ciency. However, the prevalence, aetiology and patho-
physiology of iron deﬁciency in the setting of COPD are
unknown.
In this study, we examined iron status in the Oxford
Biomedical Research Centre (BRC) COPD Cohort. We
used the traditional laboratory measures of ferritin and
transferrin saturation (TSat) as well as newer markers,
such as hepcidin and soluble transferrin receptor
(sTfR). The peptide hormone hepcidin is now under-
stood to be central to iron homoeostasis but is also
strongly inﬂuenced by the innate immune system and
erythropoietic drive. Inﬂammation elevates hepcidin,
which reduces serum iron and dietary iron absorption.12
Hepcidin is therefore important in the pathogenesis of
the anaemia of chronic disease.13 Measurement of sTfR
has emerged as a tool to distinguish between pure iron-
deﬁciency anaemia and the anaemia of chronic
disease.14 We also measured erythropoietin (EPO), C
reactive protein (CRP) and functional markers—patient-
reported outcome measures and walking distance. The
relationship between iron status and these variables was
explored.
METHODS
Patient selection criteria
The Oxford BRC COPD Cohort comprises a carefully
phenotyped group of patients with a clinical diagnosis of
COPD made according to GOLD criteria15 (forced
expiratory volume in 1 s (FEV1): forced vital capacity
(FVC) ratio <0·70 and FEV1 <80% predicted) using
standard predicted values.16 Criteria for enrolment
included the absence of other signiﬁcant cardiopulmon-
ary disease or comorbidity likely to limit life-expectancy
below 2 years. It was estimated that a sample of just over
100 patients would be needed to demonstrate a 20%
prevalence of iron deﬁciency with 80% conﬁdence and
5% precision, assuming an effectively unlimited popula-
tion. Between August 2009 and April 2012, patients
attending a specialist COPD clinic at a university hospital
were invited to enrol in the cohort. The study was con-
ducted in accordance with the Declaration of Helsinki
and approval was given by the NHS South Central
Berkshire Research Ethics Committee. Written informed
consent was given by all participants.
Control cohort
A group of healthy individuals without evidence of any
acute illness, who had been recruited for a different
study examining iron and exercise physiology (approved
by the NHS South Central Oxford B Research Ethics
Committee), provided control data for iron status.
Although this group was similar in size to the COPD
cohort, there was a greater proportion of females and
the average age was younger than for the COPD cohort.
In order to overcome these differences, a computer
algorithm was used to match cases with controls in a 2:1
ratio, and obtain a control cohort that was well matched
for sex and age.
Study design and procedures
This was an observational study in patients having stable
disease when enrolled. Assessments were undertaken
when patients reported being exacerbation-free for at
least 4 weeks and included history, record of exacerba-
tions, clinical examination and spirometry. Resting pulse
oximetry and arterial or capillary blood gas analysis were
performed, and nocturnal mean arterial oxygen satur-
ation and proportion of time spent asleep with SpO2
<90% were also determined (Konica Minolta Pulsox
300i; Stowood Scientiﬁc, UK). The St George’s
Respiratory Questionnaire (SGRQ),17 Hospital Anxiety
and Depression (HAD) score18 and Epworth Sleepiness
Score (ESS)19 were also used. All patients underwent
two Shuttle Walk Tests (SWT),20 with the better result
used for analysis. Whole blood was obtained from
patients at the same visit. Full blood count, serum iron,
TSat, ferritin and CRP were measured at a central
laboratory. Serum and plasma were obtained by centrifu-
gation and immediately frozen at −80°C for subsequent
analysis. sTfR and EPO were measured by ELISA
(Quantikine, R&D Systems, Abingdon, UK) as was
hepcidin (Hepcidin-25 EIA Kit, Bachem, Peninsula
Laboratories, San Carlos, California, USA) in accord-
ance with manufacturers’ speciﬁcations.
Definition of iron deficiency
Iron deﬁciency was deﬁned as any one or more of (1)
sTfR >28.1 nmol/L; (2) TSat <16% and (3) serum fer-
ritin <12 µg/L. Patients were classiﬁed as iron replete
(IR) if they were not iron deﬁcient (ID) and had TSat
≥20%. Patients who did not meet the deﬁnition of iron
deﬁciency but who had 16% ≤ TSat <20% were viewed
as falling into an indeterminate group. The rationale for
this deﬁnition was as follows: in clinical practice,
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measurement of serum ferritin is central to the assess-
ment of iron status with a serum ferritin level <12 µg/L
having a very high positive predictive value for absolute
iron deﬁciency.21 22 As an acute-phase reactant, however,
its utility is limited in the presence of inﬂammation.
Therefore, while low serum ferritin is diagnostic of iron
deﬁciency, normal serum ferritin cannot be used to
exclude it. The transferrin receptor allows cells to take up
iron and a proportion can be detected in a freely circulat-
ing form, sTfR. Inﬂammation does not signiﬁcantly affect
sTfR levels, which reﬂect total transferrin receptor
expression and thus unmet iron requirements. The sTfR
cut-off of 28.1 nmol/L is based on the upper reference
limit (mean plus two SDs) of the assay when used in
healthy sea-level Caucasian patients.14 A TSat ≥20% is
associated with normal red cell indices, while a value
below 16% indicates an insufﬁcient supply of iron to the
erythroid marrow,23 which will eventually manifest as a
microcytic, hypochromic anaemia.
Data analysis
Data were analysed and graphs plotted using SPSS (V.20,
IBM) and SigmaPlot (V.12.3, Systat Software).
Non-parametric data comparisons were made using the
Mann-Whitney U (MWU) test and parametric data ana-
lysed using a two-sided Student t test. To investigate the
effect of possible confounders, analysis of covariance
(ANCOVA) was used. Spearman’s rank correlation coef-
ﬁcient was calculated for analysis of correlation between
iron status rank (treating sTfR and TSat of equal import-
ance) and non-parametric variables. The algorithm used
to generate the matched control cohort was written in
MATLAB (MathWorks).
RESULTS
One hundred and sixteen patients were enrolled in the
COPD cohort, with complete laboratory data available
for 113 patients (74 men, 39 women). The cohort was
thus 65% male with a mean (SD) age of 67.6 (8.77)
years. Patients had moderately severe COPD as evi-
denced by a median FEV1 of 41% predicted, with a
median pack-year history of 43.0, the majority being
ex-smokers. All but two of the patients were Caucasians.
Five patients were receiving long-term oxygen therapy,
and nine more had access to short-burst home oxygen
(supplemental oxygen for intermittent use to relieve
severe dyspnoea). The control cohort consisted of 57
individuals, 37 (65%) of whom were male, with a mean
(SD) age of 67.6 (6.10) years. All were Caucasians.
Iron deficiency is common in COPD
Twenty patients with COPD (17.7%) were ID, 81 (71.7%)
IR and 12 (10.6%) indeterminate (ﬁgure 1A). This con-
trasts with 3 (5.3%), 51 (89.5%) and 3 (5.3%), respect-
ively, for the control cohort (p=0.029, χ2) (ﬁgure 1B).
For the COPD cohort, there were no differences between
the ID and IR groups in sex, smoking status, median
number of pack years smoked or proportion receiving
oxygen therapy. FEV1 appeared to be lower in the ID
group but this difference was not statistically signiﬁcant.
Equally, in the COPD cohort as a whole, there was not a
signiﬁcant correlation between FEV1 and any index of
iron status, be it sTfR, TSat or overall iron status rank
(r=−0.068, p=0.477; r=0.111, p=0.240 and r=0.083,
p=0.384; respectively). Characteristics of the COPD
cohort are given in table 1.
Inflammation is prevalent in COPD and associates with
iron deficiency
In the COPD cohort, 37 patients (33%) had a CRP
greater than 8 mg/L, the upper limit of normal for the
assay used (ﬁgure 2A). In contrast, there was none in
the control cohort (p<0.001, χ2). For the patients with
COPD, CRP was signiﬁcantly higher in the ID than in
the IR group (median 10.5 vs 4.0, p<0.001; ﬁgure 2B), a
relationship that persisted after adjustment for differ-
ences in FEV1 (p=0.028). The ID group had a higher
self-reported rate of exacerbations in the year prior to
enrolment (median 3 (IQR 2–6) vs 2 (IQR 1–4);
p=0.024). Again, this relationship persisted after adjust-
ment for differences in FEV1 (p=0.045).
Figure 1 (A) Venn diagram showing proportions of patients
with COPD who were iron deficient, of indeterminate iron
status or iron replete. No patients with COPD had a serum
ferritin <12 µg/L. (B) Corresponding diagram for healthy
control cohort. No healthy control participant had an sTfR
>28.1 nmol/L (COPD, chronic obstructive pulmonary disease;
sTfR, soluble transferrin receptor; TSat, transferrin saturation).
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Iron status and inflammation influence ferritin
and hepcidin levels
Figure 3 shows cumulative frequency plots for ferritin and
hepcidin. These were similar for COPD and control
cohorts. A positive correlation between hepcidin and fer-
ritin values was seen for patients with COPD as well as for
healthy controls (ﬁgure 3E). For both COPD and control
cohorts, ferritin and hepcidin levels were signiﬁcantly
lower in ID versus IR individuals (COPD cohort medians:
ferritin 28.3 vs 79.9 µg/L, p<0.001; hepcidin 21.4 vs
33.4 µg/L, p=0.013; control cohort medians: ferritin 10.5
vs 76.3 µg/L, p=0.008; hepcidin 3.33 vs 35.1 µg/L,
p=0.007). For the COPD cohort, linear regression analysis
indicated CRP was a signiﬁcant factor determining both
ferritin (p<0.001) and hepcidin (p<0.001). This was not
the case for the healthy control cohort, where CRP values
were low. Consistent with the elevation of ferritin and hep-
cidin by inﬂammation, the values for these were signiﬁ-
cantly higher in the COPD ID subgroup compared with
the control ID subgroup (median ferritin 28.3 vs 10.5 µg/L,
p=0.040; median hepcidin 21.4 vs 3.33 µg/L, p=0.020).
Iron deficiency is associated with severity of hypoxaemia
Within the COPD cohort, resting daytime SpO2 was sig-
niﬁcantly lower in the ID group, as were PO2 on a
capillary or arterial blood gas sample and mean noctur-
nal SpO2. Additionally, the proportion of time spent
with nocturnal SpO2 <90% was much higher in the ID
group. Figure 4 illustrates these ﬁndings. All these rela-
tionships persisted after adjustment for FEV1 (p<0.001,
p=0.006, p=0.001 and p=0.001, respectively).
Haemoglobin concentration does not differ according
to iron status in COPD
Haemoglobin levels were not signiﬁcantly different in
patients with COPD between ID and IR groups despite a
signiﬁcantly higher EPO level in the ID group (ﬁgure 5).
However, the mean cell volume (MCV) was lower in the
ID group (mean 88.8 vs 93.1 fL; p=0.001).
Iron status and functional performance
Exercise ability, as measured by the SWT, was worse in
the ID group (median 165 vs 240 m, p=0.035; ﬁgure 6)
but statistical signiﬁcance was lost after adjusting for dif-
ferences in FEV1 (p=0.081). Differences in SGRQ
scores, HAD scores, and ESS between ID and IR groups,
did not reach statistical signiﬁcance (mean 33.5 vs 30.1,
p=0.056; median 13.5 vs 11, p=0.133 and median 8 vs 5,
p=0.279, respectively).
Table 1 COPD cohort patient characteristics
All patients (113) Iron deficient (20) Iron replete (81) Statistical comparison
Male sex; n (%) 74 (65) 12 (60) 53 (66) χ2 (p=0.793)
Age, years; mean (SD) 67.6 (8.77) 67.5 (9.86) 67.5 (8.47) t test (p=0.980)
FEV1, % predicted; mean (SD) 43.8 (17.1) 39.7 (16.5) 44.8 (17.0) t test (p=0.236)
Current smoker; n (%) 17 (15) 4 (20) 11 (13.6) χ2 (p=0.710)
Pack years; median (IQR) 44.0 (28.5–62.0) 44.0 (37.0–67.0) 45.0 (27.8–62.8) MWU test (p=0.799)
BMI, kg/m2; median (IQR) 27.6 (21.7–30.3) 27.8 (21.6–31.9) 27.5 (21.7–30.6) MWU test (p=0.855)
Long-term oxygen therapy; n (%) 5 (4) 2 (10) 3 (4) χ2 (p=0.531)
Any home oxygen therapy; n (%) 14 (12) 5 (25) 8 (10) χ2 (p=0.151)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume in 1 s; MWU, Mann-Whitney U.
Figure 2 (A) Cumulative frequency plot for C reactive protein (CRP). Data for the chronic obstructive pulmonary disease
(COPD) cohort are plotted with a solid line and those for the control cohort with a dashed line; the shaded area indicates the
normal range for the assay. (B) Box plot (boxes show IQR and median, whiskers show 10th and 90th centiles, circles are
outliers) showing distribution of results for CRP by iron status in the COPD cohort. CRP was significantly higher in the
iron-deficient (ID) group (median 10.5 vs 4.0 mg/L, p<0.001).
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DISCUSSION
This study has demonstrated a high prevalence of non-
anaemic iron deﬁciency in COPD that may be driven by
inﬂammation. Patients with iron deﬁciency were more
hypoxaemic even though they did not have signiﬁcantly
worse airﬂow limitation. Such marked daytime and noc-
turnal hypoxaemia in the ID group was unexpected. One
possible explanation arises from the essential role of iron
as a cofactor in a key cellular pathway that senses
hypoxia, and modulates levels of the hypoxia-inducible
factor family of transcription factors.6 8 9 Tissue iron deﬁ-
ciency alters the effect of hypoxia on the pulmonary
vasculature,8 and thus may impair physiological ventila-
tion to perfusion matching and worsen hypoxaemia.
Irrespective of the underlying mechanisms, the high
prevalence of iron deﬁciency in COPD and the newly
identiﬁed association of iron deﬁciency with hypoxaemia
are potentially of considerable clinical signiﬁcance.
The major hormone that acts to determine iron avail-
ability and distribution is hepcidin. Serum levels of hep-
cidin are inﬂuenced by iron, hypoxia, erythropoietic
drive and inﬂammation.12 The importance of inﬂam-
mation in regulating iron availability in COPD is illu-
strated by the failure of the combination of iron
deﬁciency and hypoxia to suppress hepcidin completely
in the ID COPD group, whereas it is barely detectable
in the ID healthy controls. This ‘inappropriate expres-
sion’ of hepcidin is similar to that seen in the anaemia
of chronic disease.24
Within the ID COPD group, despite signiﬁcantly lower
ferritin and MCV, anaemia was uncommon and mean
haemoglobin concentration was not lower than in the IR
patients. The ID group had higher EPO levels, consist-
ent with appropriate sensing of hypoxaemia, but a
failure of the marrow to respond accordingly. It appears
as a tension exists here between erythropoietic drive and
Figure 3 (A and B) Cumulative
frequency plots for ferritin and
hepcidin. Data for the chronic
obstructive pulmonary disease
(COPD) cohort are plotted with a
solid line and those for the control
cohort with a dashed line; the
shaded area indicates the normal
range for each assay. (C and D)
Box plots showing distribution of
results for ferritin and hepcidin by
iron status in the COPD cohort.
Ferritin (median 28.3 vs 79.9 µg/L;
p<0.001) and hepcidin (median
21.4 vs 33.4 µg/L; p=0.013) were
both lower in the iron-deficient
(ID) group. (E) Scatter plot
showing relationship between
hepcidin and ferritin in the COPD
cohort (filled circles) and control
cohort (empty circles); the
regression line is for both groups
taken together; individual
regression lines were not
significantly different.
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iron availability, with inﬂammation-driven, hepcidin-
mediated iron sequestration constraining a rise in
haemoglobin. In support of this suggestion, it was noted
50 years ago that individuals with severe lung disease
tended to increment their haemoglobin only if given
intramuscular iron.25
The ﬁndings in the present study have parallels with
those from studies exploring iron homoeostasis in other
chronic respiratory diseases. In pulmonary vascular
disease, iron deﬁciency is common.26–28 In patients with
idiopathic pulmonary arterial hypertension, the preva-
lence of non-anaemic iron deﬁciency approaches
two-thirds, and severity of iron deﬁciency correlates with
WHO functional class and worsening exercise capacity,
independent of haemoglobin concentration.29 Recently,
iron deﬁciency has been shown to be associated with
worse lung function, and higher iron stores negatively
correlated with risk of asthma, in a large cohort of north
American women.30 Whether intravenous iron therapy
may be beneﬁcial for patients with idiopathic pulmonary
arterial hypertension is the subject of a large ongoing
randomised-controlled clinical trial,31 and a small pilot
study has recently described short-term improvement in
functional outcomes with intravenous iron in this
setting, though no data on pulmonary artery pressure
were reported.32 With respect to COPD, pulmonary
hypertension11 and hypoxaemia10 are both predictors of
mortality, and therefore iron deﬁciency and hypoxaemia
may interact in a particularly deleterious way in this
condition.
Figure 4 Box plots showing
distribution of (A) resting
peripheral oxygen saturation
(SpO2), (B) resting PO2 on blood
gas, (C) mean nocturnal SpO2
and (D) percentage of nocturnal
SpO2 recordings <90%, all by
iron status, in the chronic
obstructive pulmonary disease
(COPD) cohort. All measures
were significantly worse in the
iron-deficient (ID) group (medians
92 vs 95%, p<0.001; 7.97 vs
9.05 kPa, p=0.008; 88.6 vs
91.2%, p=0.015; and 75.3 vs
16.4%; p=0.005, respectively).
Figure 5 Box plots showing
distribution of (A) erythropoietin
(EPO) and (B) haemoglobin (Hb)
concentration, by iron status in
the chronic obstructive pulmonary
disease (COPD) cohort. EPO was
significantly higher in the
iron-deficient (ID) group (median
23.9 vs 13.5 mIU/mL, p=0.001)
but Hb did not differ (mean 13.4
vs 13.8 g/dL; p=0.260).
6 Nickol AH, et al. BMJ Open 2015;5:e007911. doi:10.1136/bmjopen-2015-007911
Open Access
 o
n
 25 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-007911 on 6 July 2015. Downloaded from 
In adult patients with another chronic inﬂammatory
respiratory disorder, cystic ﬁbrosis, an impaired erythro-
poietic response to hypoxaemia has also been
described,33 apparently associated with inﬂammation, as
in our COPD cohort. In a separate study, a 3-month
course of oral iron was shown not to increase haemoglo-
bin in a subgroup of patients with cystic ﬁbrosis and
functional iron deﬁciency (deﬁned as TSat <16%).34
However, a very small case series of adult patients with
cystic ﬁbrosis given intravenous iron for anaemia refrac-
tory to oral iron found that haemoglobin concentration
and MCV rose signiﬁcantly within days of therapy.35
These ﬁndings are consistent with suppression of iron
absorption by hepcidin. Figure 7 gives a schematic repre-
sentation of the inﬂuence of hepcidin in the setting of
chronic inﬂammation.
Non-invasive assessment of iron status is challenging in
COPD, as in other chronic inﬂammatory conditions,
since serum ferritin may be normal or raised despite
inadequate iron availability. None of the patients with
COPD had a serum ferritin level that would be consid-
ered strictly diagnostic of absolute iron deﬁciency.
However, the lower MCV in the ID group argues that we
did identify individuals with iron-restricted erythropoi-
esis. Importantly, the relationships observed between iron
status, hypoxaemia and inﬂammation were essentially
unchanged when additional analyses were performed
using deﬁnitions of iron deﬁciency based either solely on
low TSat, solely on raised sTfR, or on an even more
restrictive requirement for both low TSat and low sTfR.
We would therefore argue that, in this setting, each
measure detects iron sequestration, the locking-away of
iron such that it is unavailable for a particular physio-
logical process,13 and thus functional iron deﬁciency.
The ID patients in our cohort had a signiﬁcantly
higher rate of self-reported exacerbations in the preced-
ing year. This is important, since exacerbations contrib-
ute to COPD progression and strongly predict
outcome.36–38 Furthermore, our study may suggest
greater impairment of exercise capacity in ID patients
with COPD, though statistical signiﬁcance was lost after
correction for differences in FEV1. When our COPD
cohort was established, the SWTwas chosen over the self-
paced 6 min walk test because the performance has been
reported to correlate strongly with maximum oxygen
consumption,39 40 which itself may be affected by iron
deﬁciency. Numerically, the ID group managed only
two-thirds the SWT distance of their IR counterparts. The
minimum clinically important difference in the SWT,
based on data from a cohort similar to ours undergoing a
pulmonary rehabilitation programme, has been deter-
mined as 47.5 m, with patients reporting additional
beneﬁt at 78.7 m.41 Interestingly, this latter ﬁgure is
approximately the difference between medians of the ID
and IR groups. The SWT has been shown independently
to predict survival in patients with COPD, with one study
ﬁnding nearly a threefold higher mortality during an
average of 4½ years of follow-up when SWT distance fell
below 170 m,42 a value higher than the median distance
achieved by our ID group. However, one of the limita-
tions of the present study is that the size of our COPD
Figure 6 Box plots showing distribution of (A) Shuttle Walk Test (SWT) distance and (B) St George’s Respiratory Questionnaire
(SGRQ) score, by iron status in the chronic obstructive pulmonary disease (COPD) cohort. SWT distance was lower in the
iron-deficient (ID) group (median 165 vs 240 m, p=0.035) although statistical significance was lost after correction for difference in
FEV1 (p=0.081). The difference in SGRQ scores was not statistically significant (mean 33.5 vs 30.1, p=0.056).
Figure 7 Relationships between hypoxia, inflammation and
iron homoeostasis, mediated by hepcidin (EPO, erythropoietin).
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cohort limits the power of functional comparisons
between groups, so these data await validation in larger
studies. A further limitation is that our patients were
almost all Caucasian and had moderately severe COPD,
so our ﬁndings may not apply to other ethnic groups or
to those with disease of greater or lesser severity.
Recently, others have begun to consider the import-
ance of disturbed iron homoeostasis in COPD, but
anaemia continues to be a central focus.43 44 It is cer-
tainly the case that, as in other chronic conditions,
anaemia predicts a worse outcome in COPD,45 both in
the setting of admission with an acute exacerbation46
and in the long term.47 48 Taken as a whole, though, our
ﬁndings suggest greater attention should be paid to iron
deﬁciency irrespective of the presence or absence of
anaemia. Novel therapeutic possibilities include both
the manipulation of iron status through intravenous iron
therapy and, tantalisingly, hepcidin antagonists becom-
ing available.
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